Skip to main content
Nicholas Sarlis, MD, Endocrinology, Greenville, DE

NicholasJohnSarlisMDPhD, FACP

Endocrinology • Greenville, DE

Adrenal Disease, Diabetes, Lipid Metabolism, Thyroid

Chief Medical Officer - CLEARA Biotech, N.V.

Join to view full profile

Dr. Sarlis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sarlis' full profile

Already have an account?

Summary

  • As Chief Medical Officer (CMO) at CLEARA Biotech, N.V., my remit is to progress the company's compounds against 'scarred senescence'-driven malignancies, leveraging my expertise in clin. development, clin. trials, Med Affairs, Translational Oncology, and Scientific Comms. I also participate in BD&L activities, offer clin. study medical monitor services, interact with external experts (KOLs) and the Co's Supervisory Board, and manage CLEARA's Sci. Ad. Board.
    Before this role, I was CMO of The Lynx Group, LLC and then Head of Global Medical Content at Amplity Health, Inc. Prior to these engagements, I served as Executive VP and CMO - and then under contract Senior Advisor - at SELLAS Life Sciences Group, Inc. (NASDAQ, SLS), providing strategic insight on the direction of the clin. development programs for novel product candidates: peptide-based oncovaccines targeting Wilms Tumor-1 (WT1) [galinpepimut-S or GPS] and HER2 [nelipepimut-S or NPS/NeuVax] and a CDK9 inhibitor (SLS009). Prior to that role, I was heading Med. Affairs at Incyte Corp., initially in the US and then globally, supporting the launch of the original JAK inhibitor, ruxolitinib, and the IDO1 inhibitor, epacadostat. Before Incyte, held roles of increasing responsibility at Sanofi-Aventis (both in the US and globally) supporting Med Affairs.

    Before my stints in industry, I was Senior Clin. Investigator at NIH and then Assoc. Professor of Medicine at the MD Anderson Cancer Center. I received my M.D. degree and a Dr.Med.Sci. (Pharmacology) from the U. of Athens, GR, and my Ph.D. from the U. of London (UK), having completed superb clinical & basic training in the UK and the US.

    I am a Member or elected Fellow of various professional and learned societies, have received various awards, and serve as an Assoc. Editor of the J. Transl. Med. and JHOP. I have published 130+ papers, mainly with an oncology focus. I give presentations regularly in various industry and medical leadership forums worldwide.

    • CLEARA's approach to cancer metastasis mitigation and control.

    Features of 'scarred' senescent -yet hyperproliferative- cancer cells within metastases, CLEARA targets these cells via peptides that disrupt FOXO4-p53 binding.

    Cleara Biotech

    Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative

Education & Training

  • GLC Europe
    GLC EuropeMasterClass in Pharmacokinetics, PK Fundamentals and Role in Drug Development, 2023 - 2023
  • GLC Europe
    GLC EuropeMasterClass in Preclinical Toxicology, Toxicology - Fundamentals and Role in Drug Development, 2023 - 2023
  • Center for Creative Leadership (CCL), Inc.
    Center for Creative Leadership (CCL), Inc.Senior Leadership Curriculum Completion (with Certification), Corporate Leadership, 2013 - 2013
  • Wharton/ Windhover Program; Aresty Institute of Executive Education
    Wharton/ Windhover Program; Aresty Institute of Executive EducationExecutives Curriculum Completion (with Certification), Corporate Management, 2007 - 2007
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1995 - 1997
  • University of Utah Health
    University of Utah HealthResidency, Internal Medicine, 1993 - 1995
  • University of Utah Health
    University of Utah HealthInternship, Internal Medicine, 1992 - 1993
  • Imperial College London (ICL); Charing Cross & Westminster Med School
    Imperial College London (ICL); Charing Cross & Westminster Med SchoolPhD, Neuroendocrinology, Cum Laude, 1989 - 1992
  • University of Athens School of Medicine
    University of Athens School of MedicineDr. Med. Sci., Exper Pharmacology, Hons., 1988 - 1989
  • University of Athens
    University of AthensClass of 1988, MBBS (MD equivalent), Valedictorian
  • College de France
    College de FranceLaboratory techniques training, Cell Biology, Embryology, Histology, 1984 - 1985

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1996 - 2025
  • TX State Medical License
    TX State Medical License 2003 - 2025
  • UT State Medical License
    UT State Medical License 1993 - 1995
  • National Board of Physicians and Surgeons Endocrinology Diabetes and Metabolism
  • National Board of Physicians and Surgeons Internal Medicine
  • Clinical Nutrition Certification Board (CNCB)Certification in Clinical Nutrition (C.C.N.)
  • U.S. Nuclear Regulatory Commission (NRC) Authorized User for Human Use of Radionuclides

Awards, Honors, & Recognition

  • Key Contributor Award Paris Immuno-Oncology Summit 2017 - Inaugural Meeting, 2017
  • Lifetime Achievement Award Cancer Research & Treatment Fund, New York, NY, 2016
  • Lifelong Distinguished VIP Membership Award Bristol Who-is-Who, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pharmacokinetic Study of 2 Formulations of GFH009 Maleate Injection in SD Rats.  
    Fu-Sheng Zhou, Jin-Zhu Zhao, Hong-Can Ren, Dragan Cicic, Nicholas J Sarlis, Jiong Lan, Qiang Lu, Am J Pharmacol Pharmacother., 6/26/2023
  • Recent Progress in the Biomarker Landscape for Gastrointestinal Malignancies.  
    Nicholas J Sarlis, The Oncology Nurse, 6/1/2021
  • The interplay between inhibition of JAK2 and HSP90.  
    Fridman JS, Sarlis NJ, JAK-STAT

Abstracts/Posters

  • Peptide-based pivoting of ‘scarred’ p53 to target metastatic breast cancer.
    Putavet DA, Baar MP, Lehmann JH, Khalil A, Shi T, Bouma E, Koorman T, Dansen TB, de Rooij J, Derksen PWB, Teifel M, Madl T, Sarlis NJ, de Keizer PLJ., AACR Annual Meeting; Abst. # 2095/19, San Diego, CA, USA, 4/8/2024
  • Disease Phenotype Discovery and Validation Can Optimally Inform Target Selection and Drug Development: Application of Artificial Intelligence-Based Analytics Using Rea...
    Nicholas J. Sarlis, Michael N. Liebman, American Federation for Medical Research (AFMR), Reston, VA, USA, 10/27/2023

Lectures

  • Clinical Trials of a WT1 Multivalent Peptide Vaccine 
    International conference on WT1 biology, Nice, France - 5/21/2019
  • Has the Time Come for Chemo-& Immuno-Prevention: Nixing the Nabobs of Negativity 
    30th Cancer Progress Conference, New York, NY, USA - 5/7/2019
  • Innovations in academic industry partnerships 
    Translational Science 2018 Meeting, Washington, DC, USA - 4/21/2018
  • Join now to see all

Press Mentions

  • CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development
    CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical DevelopmentFebruary 22nd, 2023
  • CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development
    CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical DevelopmentFebruary 22nd, 2023
  • CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development
    CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical DevelopmentFebruary 22nd, 2023
  • Join now to see all

Grant Support

  • Clinically Aggressive Thyroid Cancer: Molecular Basis AnNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2002
  • Clinically Aggressive Thyroid Cancer: Molecular Basis And Treatment OutcomeNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2000

Professional Memberships

Other Languages

  • French, German, Greek

Industry Relationships

  • Chief Medical Officer, CLEARA Biotech BVEmployment as Chief Medical Officer and Head of Drug Development.2022 - 2023
  • Chief Medical Officer (Contracted), Sellas Life Sciences Group, Inc.Full Professional profile shown below: Public Profile http://www.linkedin.com/pub/nicholas-sarlis-md-phd-facp/4/609/39/Disclosure: Equity shareholder2019 - 2020

External Links

Dr. Nicholas Sarlis, Dr. Nicholas Sarlis, MD, Dr. N Sarlis, Dr. Nicholas John Sarlis